GENMAB A/S -SP ADR (GMAB) Stock Fundamental Analysis
USA - NASDAQ:GMAB - US3723032062 - ADR
29.89 USD
+0.02 (+0.07%)
30 USD
+0.11 (+0.37%)
Taking everything into account, GMAB scores 7 out of 10 in our fundamental rating. GMAB was compared to 534 industry peers in the Biotechnology industry. GMAB has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. GMAB has a correct valuation and a medium growth rate. These ratings would make GMAB suitable for quality investing!
1. Profitability
1.1 Basic Checks
In the past year GMAB was profitable.
GMAB had a positive operating cash flow in the past year.
In the past 5 years GMAB has always been profitable.
GMAB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 19.60%, GMAB belongs to the top of the industry, outperforming 96.63% of the companies in the same industry.
GMAB has a Return On Equity of 23.90%. This is amongst the best in the industry. GMAB outperforms 96.44% of its industry peers.
GMAB's Return On Invested Capital of 16.37% is amongst the best of the industry. GMAB outperforms 96.63% of its industry peers.
The Average Return On Invested Capital over the past 3 years for GMAB is in line with the industry average of 15.49%.
The last Return On Invested Capital (16.37%) for GMAB is above the 3 year average (15.20%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.6% | ||
| ROE | 23.9% | ||
| ROIC | 16.37% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
1.3 Margins
GMAB has a better Profit Margin (37.52%) than 97.38% of its industry peers.
GMAB's Profit Margin has declined in the last couple of years.
The Operating Margin of GMAB (34.75%) is better than 97.94% of its industry peers.
GMAB's Operating Margin has declined in the last couple of years.
GMAB's Gross Margin of 94.45% is amongst the best of the industry. GMAB outperforms 94.19% of its industry peers.
GMAB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 34.75% | ||
| PM (TTM) | 37.52% | ||
| GM | 94.45% |
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so GMAB is creating value.
Compared to 1 year ago, GMAB has less shares outstanding
The number of shares outstanding for GMAB has been reduced compared to 5 years ago.
GMAB has a worse debt/assets ratio than last year.
2.2 Solvency
GMAB has an Altman-Z score of 12.00. This indicates that GMAB is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 12.00, GMAB belongs to the best of the industry, outperforming 84.83% of the companies in the same industry.
The Debt to FCF ratio of GMAB is 0.15, which is an excellent value as it means it would take GMAB, only 0.15 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.15, GMAB belongs to the top of the industry, outperforming 96.25% of the companies in the same industry.
A Debt/Equity ratio of 0.02 indicates that GMAB is not too dependend on debt financing.
GMAB's Debt to Equity ratio of 0.02 is in line compared to the rest of the industry. GMAB outperforms 41.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.15 | ||
| Altman-Z | 12 |
ROIC/WACC2.35
WACC6.97%
2.3 Liquidity
A Current Ratio of 6.22 indicates that GMAB has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.22, GMAB is in the better half of the industry, outperforming 65.17% of the companies in the same industry.
GMAB has a Quick Ratio of 6.20. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
GMAB has a better Quick ratio (6.20) than 65.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.22 | ||
| Quick Ratio | 6.2 |
3. Growth
3.1 Past
GMAB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -69.50%.
Measured over the past 5 years, GMAB shows a small growth in Earnings Per Share. The EPS has been growing by 0.56% on average per year.
GMAB shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.79%.
The Revenue has been growing by 31.16% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-69.5%
EPS 3Y-8.61%
EPS 5Y0.56%
EPS Q2Q%73.04%
Revenue 1Y (TTM)22.79%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-82.88%
3.2 Future
Based on estimates for the next years, GMAB will show a decrease in Earnings Per Share. The EPS will decrease by -4.41% on average per year.
Based on estimates for the next years, GMAB will show a quite strong growth in Revenue. The Revenue will grow by 14.74% on average per year.
EPS Next Y-51.98%
EPS Next 2Y-24.93%
EPS Next 3Y-10.89%
EPS Next 5Y-4.41%
Revenue Next Year22.18%
Revenue Next 2Y19.2%
Revenue Next 3Y17.29%
Revenue Next 5Y14.74%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
GMAB is valuated correctly with a Price/Earnings ratio of 14.87.
96.63% of the companies in the same industry are more expensive than GMAB, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.91. GMAB is valued slightly cheaper when compared to this.
With a Price/Forward Earnings ratio of 15.15, GMAB is valued correctly.
GMAB's Price/Forward Earnings ratio is rather cheap when compared to the industry. GMAB is cheaper than 94.76% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.92, GMAB is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.87 | ||
| Fwd PE | 15.15 |
4.2 Price Multiples
95.69% of the companies in the same industry are more expensive than GMAB, based on the Enterprise Value to EBITDA ratio.
94.94% of the companies in the same industry are more expensive than GMAB, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.14 | ||
| EV/EBITDA | 11.33 |
4.3 Compensation for Growth
The excellent profitability rating of GMAB may justify a higher PE ratio.
A cheap valuation may be justified as GMAB's earnings are expected to decrease with -10.89% in the coming years.
PEG (NY)N/A
PEG (5Y)26.55
EPS Next 2Y-24.93%
EPS Next 3Y-10.89%
5. Dividend
5.1 Amount
GMAB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
29.89
+0.02 (+0.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners38.32%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap18.40B
Revenue(TTM)3.38B
Net Income(TTM)1.27B
Analysts76.15
Price Target60.61 (102.78%)
Short Float %0.94%
Short Ratio2.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)37.39%
Min EPS beat(2)25.14%
Max EPS beat(2)49.64%
EPS beat(4)3
Avg EPS beat(4)49.63%
Min EPS beat(4)-10.91%
Max EPS beat(4)134.67%
EPS beat(8)6
Avg EPS beat(8)33.01%
EPS beat(12)8
Avg EPS beat(12)22.43%
EPS beat(16)12
Avg EPS beat(16)30.18%
Revenue beat(2)0
Avg Revenue beat(2)-4.57%
Min Revenue beat(2)-7.66%
Max Revenue beat(2)-1.49%
Revenue beat(4)2
Avg Revenue beat(4)137.93%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)559%
Revenue beat(8)6
Avg Revenue beat(8)147.09%
Revenue beat(12)8
Avg Revenue beat(12)84.14%
Revenue beat(16)8
Avg Revenue beat(16)41.97%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-2.73%
EPS NQ rev (3m)1.13%
EPS NY rev (1m)1.4%
EPS NY rev (3m)-84.74%
Revenue NQ rev (1m)0.56%
Revenue NQ rev (3m)3.16%
Revenue NY rev (1m)-0.21%
Revenue NY rev (3m)-85.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.87 | ||
| Fwd PE | 15.15 | ||
| P/S | 5.45 | ||
| P/FCF | 19.14 | ||
| P/OCF | 17.74 | ||
| P/B | 3.47 | ||
| P/tB | 5.76 | ||
| EV/EBITDA | 11.33 |
EPS(TTM)2.01
EY6.72%
EPS(NY)1.97
Fwd EY6.6%
FCF(TTM)1.56
FCFY5.22%
OCF(TTM)1.69
OCFY5.64%
SpS5.49
BVpS8.61
TBVpS5.19
PEG (NY)N/A
PEG (5Y)26.55
Graham Number19.74
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.6% | ||
| ROE | 23.9% | ||
| ROCE | 20.11% | ||
| ROIC | 16.37% | ||
| ROICexc | 32.53% | ||
| ROICexgc | 115.22% | ||
| OM | 34.75% | ||
| PM (TTM) | 37.52% | ||
| GM | 94.45% | ||
| FCFM | 28.47% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
ROICexc(3y)68.77%
ROICexc(5y)79.83%
ROICexgc(3y)104.16%
ROICexgc(5y)104.49%
ROCE(3y)18.68%
ROCE(5y)19.78%
ROICexgc growth 3Y22.66%
ROICexgc growth 5Y11.4%
ROICexc growth 3Y-22.7%
ROICexc growth 5Y-14.09%
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
F-Score7
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.15 | ||
| Debt/EBITDA | 0.11 | ||
| Cap/Depr | 117.22% | ||
| Cap/Sales | 2.25% | ||
| Interest Coverage | 203.86 | ||
| Cash Conversion | 83.77% | ||
| Profit Quality | 75.86% | ||
| Current Ratio | 6.22 | ||
| Quick Ratio | 6.2 | ||
| Altman-Z | 12 |
F-Score7
WACC6.97%
ROIC/WACC2.35
Cap/Depr(3y)96.21%
Cap/Depr(5y)101.76%
Cap/Sales(3y)1.96%
Cap/Sales(5y)2.38%
Profit Quality(3y)107.36%
Profit Quality(5y)103.53%
High Growth Momentum
Growth
EPS 1Y (TTM)-69.5%
EPS 3Y-8.61%
EPS 5Y0.56%
EPS Q2Q%73.04%
EPS Next Y-51.98%
EPS Next 2Y-24.93%
EPS Next 3Y-10.89%
EPS Next 5Y-4.41%
Revenue 1Y (TTM)22.79%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-82.88%
Revenue Next Year22.18%
Revenue Next 2Y19.2%
Revenue Next 3Y17.29%
Revenue Next 5Y14.74%
EBIT growth 1Y34.91%
EBIT growth 3Y29.8%
EBIT growth 5Y21.02%
EBIT Next Year50.35%
EBIT Next 3Y30.08%
EBIT Next 5Y16.89%
FCF growth 1Y19.93%
FCF growth 3Y51.06%
FCF growth 5Y42.84%
OCF growth 1Y20.82%
OCF growth 3Y47.08%
OCF growth 5Y41.48%
GENMAB A/S -SP ADR / GMAB FAQ
What is the ChartMill fundamental rating of GENMAB A/S -SP ADR (GMAB) stock?
ChartMill assigns a fundamental rating of 7 / 10 to GMAB.
What is the valuation status of GENMAB A/S -SP ADR (GMAB) stock?
ChartMill assigns a valuation rating of 6 / 10 to GENMAB A/S -SP ADR (GMAB). This can be considered as Fairly Valued.
Can you provide the profitability details for GENMAB A/S -SP ADR?
GENMAB A/S -SP ADR (GMAB) has a profitability rating of 8 / 10.
What is the valuation of GENMAB A/S -SP ADR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for GENMAB A/S -SP ADR (GMAB) is 14.87 and the Price/Book (PB) ratio is 3.47.
What is the earnings growth outlook for GENMAB A/S -SP ADR?
The Earnings per Share (EPS) of GENMAB A/S -SP ADR (GMAB) is expected to decline by -51.98% in the next year.